CERVARIX -FDA Response Letter
GlaxoSmithKline PLC
17 December 2007
Issued - December 17, 2007, London, UK & Philadelphia, US
GLAXOSMITHKLINE RECEIVES FDA 'COMPLETE RESPONSE' LETTER FOR
CERVICAL CANCER VACCINE
GlaxoSmithKline (NYSE: GSK) announced today that it has received a complete
response letter from the U.S. Food and Drug Administration related to its
application for the cervical cancer vaccine, CERVARIX(R). A complete response
letter is issued by FDA's Center for Biologics Evaluation and Research (CBER)
when the review of a file is completed and questions remain to be answered prior
to approval. GSK will work closely with the FDA to prepare its response, which
it intends to submit to the agency as soon as possible.
"We have already started addressing the questions and will be engaged in
discussions with the FDA to finalize our responses," said Barbara Howe, M.D.,
Vice President and Director, North American Vaccine Development,
GlaxoSmithKline. "Our discussions with the agency continue to be positive and
constructive, and we are working diligently to resolve any outstanding questions
to bring CERVARIX(R) to the U.S. market."
The application filed for the GSK cervical cancer vaccine included safety,
efficacy and immune response data from clinical trials involving almost 30,000
females 10 to 55 years of age from ethnically and racially diverse populations.
To date, CERVARIX(R) has been approved in 45 countries around the world
including the 27 member countries of the European Union, Mexico, Australia,
Singapore and the Philippines. Licensing applications have been submitted in
more than 27 additional countries including Japan. GSK also submitted
CERVARIX(R) to the World Health Organization (WHO) for prequalification in
September 2007.
S M Bicknell
Company Secretary
17th December 2007
Notes to Editors
Burden of Cervical Cancer
Worldwide, more than 500,000 women will be newly diagnosed with cervical cancer
and over 280,000 women will die from it each year.1 In the United States, after
breast cancer, cervical cancer is the second leading cause of cancer death in
women ages 20 to 39.2
About GlaxoSmithKline
GlaxoSmithKline-one of the world's leading research-based pharmaceutical and
healthcare companies-is committed to improving the quality of human life by
enabling people to do more, feel better and live longer. For company
information, please visit www.gsk.com/media.
GSK Biologicals (GSK Bio), one of the world's leading vaccine manufacturers, is
headquartered in Rixensart, Belgium, where the majority of GlaxoSmithKline's
activities in the field of vaccine research, development and production are
conducted. GSK Bio employs more than 1,500 scientists, who are devoted to
discovering new vaccines and developing more cost-effective and convenient
combination products to prevent infections that cause serious medical problems
worldwide. In 2006, GSK Bio distributed more than 1.1 billion doses of vaccines
to 169 countries in both the developed and the developing world - an average of
3 million doses a day. Of those vaccine doses, approximately 136 million were
doses of combination pediatric vaccines which protect the world's children from
up to six diseases in one vaccine.
CERVARIX(R) is a registered trademark of the GlaxoSmithKline group of companies.
Cautionary statement regarding forward-looking statements
Under the safe harbor provisions of the U.S. Private Securities Litigation
Reform Act of 1995, the company cautions investors that any forward-looking
statements or projections made by the company, including those made in this
Announcement, are subject to risks and uncertainties that may cause actual
results to differ materially from those projected. Factors that may affect the
Group's operations are described under 'Risk Factors' in the 'Business Review'
in the company's Annual Report on Form 20-F for 2006.
References:
1. World Health Organization. Initiative for Vaccine Research.
http://www.who.int/vaccine_research/diseases/hpv/en/ Accessed on May 2, 2007.
2. Jemal A, Murray T, Ward E, Sammuels A et al. Cancer Statistics, 2005.
Cancer Journal for Clinicians 2005; 55; 10-30
Enquiries:
UK Media enquiries: Philip Thomson (020) 8047 5502
Alice Hunt (020) 8047 5502
Joss Mathieson (020) 8047 5502
Claire Brough (020) 8047 5502
US Media enquiries: Nancy Pekarek (215) 751 7709
Mary Anne Rhyne (919) 483 2839
Liad Diamond (919) 483 2839
European Analyst/Investor enquiries: David Mawdsley (020) 8047 5564
Sally Ferguson (020) 8047 5543
US Analyst/ Investor enquiries: Frank Murdolo (215) 751 7002
Tom Curry (215) 751 5419
Biologicals: Stella Gu +32 2 656 3533
Alice Grasset +32 2 656 8774
This information is provided by RNS
The company news service from the London Stock Exchange
Latest directors dealings
- 14 hours ago Savannah Energy
- 15 hours ago Buccaneer Energy PLC
- 15 hours ago Savannah Energy
- 16 hours ago Carclo
- 16 hours ago Schroder Japan Growth Fund